Excellent review article by @ptarantinomd.bsky.social on redefining Her-2 testing @ethicsdoctorp.bsky.social @acochran12733.bsky.social ascopubs.org/doi/10.1200/... @oncoalert.bsky.social

✨EXCLUSIVE PREVIEW: Ahead of the 2025 @ascocancer.bsky.social Annual Meeting, breast cancer experts highlight this year's most anticipated abstracts @stolaney1.bsky.social @ptarantinomd.bsky.social #ASCO25 #bcsm www.onclive.com/view/breast-...

Paolo Tarantino: Glad to have had Giacomo De Micheli at Dana-Farber’s Breast Oncology Center - OncoDaily Paolo Tarantino: Glad to have had Giacomo De Micheli at Dana-Farber’s Breast Oncology Center / cancer, DFCI, OncoDaily, Oncology, Paolo Tarantino, Sara Tolaney

Glad to have had Giacomo De Micheli at Dana-Farber’s Breast Oncology Center - Paolo Tarantino
@ptarantinomd.bsky.social
@stolaney1.bsky.social
@dfcibreastonc.bsky.social

oncodaily.com/blog/paolo-t...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Paolo Tarantino Highlights ESMO Breast 25 as ESMO Ambassador - OncoDaily Paolo Tarantino Highlights ESMO Breast 25 as ESMO Ambassador / Breast Cancer, cancer, ESMO, ESMO Ambassadors, ESMO Breast 25, OncoDaily, Oncology, Paolo

Paolo Tarantino Highlights ESMO Breast 25 as ESMO Ambassador
@ptarantinomd.bsky.social
@myesmo.bsky.social

oncodaily.com/blog/paolo-t...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMOBreast25 #ESMO

#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation. #bcsm
🔗 ow.ly/VtAE50VP4Jf

Congratulations to Drs. Paolo Tarantino, Caterina Sposetti, Pietro De Placido, and Tess O'Meara on receiving the prestigious #ConquerCancer #ASCO Merit Awards!
@ptarantinomd.bsky.social @csposettimd.bsky.social

Don't miss "The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development," a Cancer Discovery review by #AACR25 speakers Elisabeth de Vries and @raffcolo.bsky.social (along with Pat LoRusso & @ptarantinomd.bsky.social) doi.org/10.1158/2159...

Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer - OncoDaily Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer / Breast Cancer, cancer, Dana-Farber Cancer Institute, OncoDaily,

Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer
@ptarantinomd.bsky.social

oncodaily.com/blog/paolo-t...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ADCs #BreastCancer

Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.

Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment
@ptarantinomd.bsky.social @danafarbernews.bsky.social #BreastCancer
www.onclive.com/view/novel-a...

Paolo Tarantino: St. Gallen Consensus 2025 - 10 key votes - OncoDaily Paolo Tarantino: St. Gallen Consensus 2025 - 10 key votes / Breast Cancer, breast oncology, cancer, Dana-Farber Cancer Institute, fight against cancer, G

St. Gallen Consensus 2025 – 10 key votes - Paolo Tarantino
@ptarantinomd.bsky.social

oncodaily.com/blog/paolo-t...

#Cancer #Medicine #Health #BreastCancer #CancerConference #Oncology #OncoDaily

Register for the @OncLive Breast Cancer State of the Science Summit at the Hilton Boston in Back Bay on March 26th, hosted by Dr. Paolo Tarantino @ptarantinomd.bsky.social. All are free to attend including doctors, nurses, pharmacists, clinical researchers, etc.
👉 event.onclive.com/QVZ54b?RefId...

Paolo Tarantino: A pleasure to join the gender balance session at JSMO25 - OncoDaily Paolo Tarantino: A pleasure to join the gender balance session at JSMO25 / cancer, JSMO25, OncoDaily, Oncology, Paolo Tarantino

A pleasure to join the gender balance session at JSMO25 - Paolo Tarantino
@ptarantinomd.bsky.social

oncodaily.com/blog/253704

#Cancer #CancerResearch #Medicine #Health #JSMO25 #Oncology #OncoDaily

2025 is anticipated to be the year with the highest number of phase 3 ADC trials read outs in breast oncology, with impact for all breast cancer subtypes.

Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:

Check out this new systematic review and meta-analysis discussing #AntibodyDrugConjugates in patients with advanced/metastatic HER2-low-expressing #BreastCancer.
🔓https://pubmed.ncbi.nlm.nih.gov/39574495/
@ptarantinomd.bsky.social

No standing ovations at #SABCS24, but maybe there should have been! 🎤 (Granted, I didn’t catch everything in the room.)

For MBC, the #PATINA and #EMBER data bring meaningful progress for patients with ER+ & triple-positive breast cancer. Exciting strides being made.

Dr. Bianchini describes the 🐘 in the room at #SABCS24.

❓Are PD-L1 and PD1 not created equal in breast?

🔑It is clear, neoadjuvant compared to adj immunotherapy should be given

⚠️ highlights ER low should be included in ICI trials

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social

Great discussion of novel biomarkers and HER2-targeted TKIs by @ptarantinomd.bsky.social @dfcibreastonc.bsky.social

📌“Optimizing outcomes for HER2-expressing breast cancer through novel biomarkers and TKIs”
Great discussion by @ptarantinomd.bsky.social 👏🏻
#SABCS24 #day3 @oncoalert.bsky.social #OncoAlertAF @danafarber.bsky.social

‼️When you thought you had the #SABCS24 program figured out, here’s the PRACTICE-CHANGING #PATINA trial being added!

For the impatient ones, press release here: www.businesswire.com/news/home/20...

If you’re in San Anyonio, though, make sure to attend the data presentation today by Otto Metzger!

Dr. Paolo Tarantino (@ptarantinomd.bsky.social) will serve as a moderator in the #SABCS24 Educational Session 7. He will also give a presentation titled “Aiming for the Target: Increasing the Precision of #ADCs through Novel Biomarkers and Innovative Molecular Constructs”

📌Education Session: People's Choice -The Future in Antibody Drug Conjugates
Topic 1: “The ABC of ADCs: History, Mechanism of Action, Mechanisms of Resistance” by John Lambert 👏🏻
Moderator Introduction by @ptarantinomd.bsky.social 👏🏻
#SABCS24 #day2 @oncoalert.bsky.social #OncoAlertAF

Dr. Paolo Tarantino (@ptarantinomd.bsky.social) will be the invited discussant for Session 8: “Novel HER2 Therapeutics” at #SABCS24, his discussion will focus on #RadiationOncology.

🗓️ Thursday, December 12th
⏰ 7:30 - 7:45 am CST (8:30 – 8:45 am EST)
📍 Stars at Night 1-2

Outstanding spotlight poster discussion by Thomas Grinda from Gustave Roussy. Promising results with the 1L combination of chemo, IO and VEGF blockade for mTNBC. Will the inclusion of IO in the combo change the story of VEGF, previously thought not to improve long-term outcomes for breast cancer?

#SABCS24 day 1 kicks off with an interesting @FDAOncology special session on drug approval. First talk tackles the approval of adjuvant ribociclib per NATALEE. Two post-marketing commitments: to provide efficacy in a broader diverse population, and to provide updates on OS. #bcsm

Paolo Tarantino: Upcoming SABCS24 session on the future of ADCs - OncoDaily Paolo Tarantino: Upcoming SABCS24 session on the future of ADCs / cancer, OncoDaily, Oncology, Paolo Tarantino, SABCS 2024

Upcoming SABCS24 session on the future of ADCs - Paolo Tarantino

oncodaily.com/blog/201316

@ptarantinomd.bsky.social

#Cancer #OncoDaily #Oncology #SABCS2024 #Medicine #Health

Awesome #SABCS24 starter pack! 👇

Small preview from Wednesday’s #SABCS24 session on the future of ADCs

Question: what do all these ongoing phase 3 ADC trials have in common?

🗓️ Dec 11, 3.30 pm, Hemisfair Ballroom 1-2

#SABCS24 here we go!!

The @dfcibreastonc.bsky.social team is on its way— see you all soon in San Antonio! #SABCS24